BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

880 related articles for article (PubMed ID: 18728028)

  • 1. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
    Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
    Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dose-reduced Medac L-asparaginase on coagulation in trial ALL-BFM 2000.
    Attarbaschi A; Mann G; Kronberger M; Witt V; Gadner H; Dworzak M
    Klin Padiatr; 2003; 215(6):321-6. PubMed ID: 14677096
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia.
    Beinart G; Damon L
    Am J Hematol; 2004 Dec; 77(4):331-5. PubMed ID: 15551293
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Erwinia- and E. coli-derived L-asparaginase have similar effects on hemostasis. Pilot study in 10 patients with acute lymphoblastic leukemia.
    Castaman G; Rodeghiero F
    Haematologica; 1993; 78(6 Suppl 2):57-60. PubMed ID: 8039761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
    Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
    Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of glucocorticoids, E. coli- and Erwinia L-asparaginase on hemostatic proteins in children with acute lymphoblastic leukemia.
    Mall V; Thomas KB; Sauter S; Niemeyer CM; Sutor AH
    Klin Padiatr; 1999; 211(4):205-10. PubMed ID: 10472551
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia.
    Merlen C; Bonnefoy A; Wagner E; Dedeken L; Leclerc JM; Laverdière C; Rivard GE
    Pediatr Blood Cancer; 2015 Aug; 62(8):1381-7. PubMed ID: 25820776
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A regimen for antithrombin III substitution in patients with acute lymphoblastic leukemia under treatment with L-asparaginase.
    Mattioli Belmonte M; Gugliotta L; Delvos U; Catani L; Vianelli N; Cascione ML; Belardinelli AR; Mottola L; Tura S
    Haematologica; 1991; 76(3):209-14. PubMed ID: 1743591
    [TBL] [Abstract][Full Text] [Related]  

  • 9. L-Asparaginase and the effect of age on coagulation and fibrinolysis in childhood acute lymphoblastic leukemia.
    Appel IM; Hop WC; van Kessel-Bakvis C; Stigter R; Pieters R
    Thromb Haemost; 2008 Aug; 100(2):330-7. PubMed ID: 18690355
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
    Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
    Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fractionated cyclophosphamide added to the IVAP regimen (idarubicin-vincristine-L-asparaginase-prednisone) could lower the risk of primary refractory disease in T-lineage but not B-lineage acute lymphoblastic leukemia: first results from a phase II clinical study.
    Bassan R; Pogliani E; Lerede T; Fabris P; Rossi G; Morandi S; Casula P; Lambertenghi-Deliliers G; Vespignani M; Izzi T; Coser P; Corneo G; Barbui T
    Haematologica; 1999 Dec; 84(12):1088-93. PubMed ID: 10586210
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in hypercoagulability by asparaginase: a randomized study between two asparaginases.
    Appel IM; Hop WC; Pieters R
    Blood Coagul Fibrinolysis; 2006 Mar; 17(2):139-46. PubMed ID: 16479196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of disease and chemotherapy on hemostasis in children with acute lymphoid leukemia.
    Mitchell LG; Halton JM; Vegh PA; Barr RD; Venneri T; Pai KM; Andrew ME
    Am J Pediatr Hematol Oncol; 1994 May; 16(2):120-6. PubMed ID: 8166364
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
    Mitchell L; Andrew M; Hanna K; Abshire T; Halton J; Wu J; Anderson R; Cherrick I; Desai S; Mahoney D; McCusker P; Chait P; Abdolell M; de Veber G; Mikulis D
    Thromb Haemost; 2003 Aug; 90(2):235-44. PubMed ID: 12888870
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inefficacy of fresh frozen plasma in the treatment of L-asparaginase-induced coagulation factor deficiencies during ALL induction therapy.
    Nowak-Göttl U; Rath B; Binder M; Hassel JU; Wolff J; Husemann S; Ritter J
    Haematologica; 1995; 80(5):451-3. PubMed ID: 8566890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cerebral thrombosis in a child with acute lymphocytic leukemia during L-asparaginase therapy].
    Horigome Y; Hanada T; Inudoh M; Takita H
    Rinsho Ketsueki; 1989 Aug; 30(8):1284-8. PubMed ID: 2601047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hemostatic changes in children with acute lymphoblastic leukemia treated according to two different L-asparaginase schedules.
    Miniero R; Pastore G; Saracco P; Messina M; Lange MM; Fiandino G; Iannacci L; Madon E
    Am J Pediatr Hematol Oncol; 1986; 8(2):116-20. PubMed ID: 3461716
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of low-molecular-weight heparin and antithrombin versus antithrombin alone for the prevention of symptomatic venous thromboembolism in children with acute lymphoblastic leukemia.
    Meister B; Kropshofer G; Klein-Franke A; Strasak AM; Hager J; Streif W
    Pediatr Blood Cancer; 2008 Feb; 50(2):298-303. PubMed ID: 17443678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antithrombin supplementation III in childhood acute lymphoblastic leukemia treated with L-asparaginase.
    Matsuzaki A; Suminoe A; Hara T
    Pediatr Hematol Oncol; 2002 Dec; 19(8):601-3. PubMed ID: 12487838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term results of a randomized trial on extended use of high dose L-asparaginase for standard risk childhood acute lymphoblastic leukemia.
    Pession A; Valsecchi MG; Masera G; Kamps WA; Magyarosy E; Rizzari C; van Wering ER; Lo Nigro L; van der Does A; Locatelli F; Basso G; Aricò M
    J Clin Oncol; 2005 Oct; 23(28):7161-7. PubMed ID: 16192600
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 44.